Orbimed Advisors LLC bought $20M of ETRA
director, owner at Electra Therapeutics, Inc.. 1,333,333 shares at an average of $15.00, traded Sep 21, 2026, filed Sep 23, 2026.
Score components
- +15RoleDirector
- +25Trade size$20.0M at market
- +6Relative to holdingsHoldings up 28%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000880, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | CConversion Common Stockindirect: See footnotes | +2,002,310 | - | - | 2,002,310 | 19 d ago |
| Sep 21, 2026 | CConversion Common Stockindirect: See footnotes | +1,087,934 | - | - | 3,090,244 | 19 d ago |
| Sep 21, 2026 | CConversion Common Stockindirect: See footnotes | +1,703,314 | - | - | 4,793,558 | 19 d ago |
| Sep 21, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +333,333 | $15.00 | $5.0M | 5,126,891 | 19 d ago |
| Sep 21, 2026 | CConversion Common Stockindirect: See footnotes | +758,279 | - | - | 758,279 | 19 d ago |
| Sep 21, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,758,279 | 19 d ago |
| Sep 21, 2026 | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnotes | -2,002,310 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnotes | -1,087,934 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -1,703,314 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -758,279 | $0.00 | $0 | 0 | 19 d ago |
Related signals
Other insiders at Electra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Electra Therapeutics, Inc. | Carl L Gordon director, owner | $20M 1,333,333 shares | +28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.